Sex-Specific Differences in Toxicity Following Systemic Paclitaxel Treatment and Localized Cardiac Radiotherapy
Authors:
- Nicole Chmielewski-StiversNCNicole Chmielewski-Stivers
- Benoit PetitBPBenoit Petit
- Jonathan OllivierJOJonathan Ollivier
- Virginie MonceauVirginie Monceau
- Pelagia TsoutsouPTPelagia Tsoutsou
- Ana Quintela PousaAPAna Quintela Pousa
- Xiaomeng LinXLXiaomeng Lin
- Charles LimoliCharles Limoli
- Marie-Catherine VozeninMVMarie-Catherine Vozenin
Open Access
Abstract
The impact of sex in the development of long-term toxicities affecting the quality of life of cancer survivors has not been investigated experimentally. To address this issue, a series of neurologic and cardiologic endpoints were used to investigate sex-based differences triggered by paclitaxel treatment and radiotherapy exposure. Male and female wild-type (WT) mice were treated with paclitaxel (150 and 300 mg/kg) administered weekly over 6 weeks or exposed to 19 Gy cardiac irradiation. Cohorts were analyzed for behavioral and neurobiologic endpoints to assess systemic toxicity of paclitaxel or cardiovascular endpoints to assess radiotherapy toxicity. Interestingly, female WT mice exhibited enhanced tolerance compared to male WT mice regardless of the treatment regimen. To provide insight into the possible sex-specific protective mechanisms, rhoB-deficient animals and elderly mice (22 months) were used with a focus on the possible contribution of sex hormones, including estrogen. In females, RhoB deficiency and advanced age had no impact on neurocognitive impairment induced by paclitaxel but enhanced cardiac sensitivity to radiotherapy. Conversely, rhoB-deficiency protected males from radiation toxicity. In sum, RhoB was identified as a molecular determinant driving estrogen-dependent cardioprotection in female mice, whereas neuroprotection was not sex hormone dependent. To our knowledge, this study revealed for the first time sex- and organ-specific responses to paclitaxel and radiotherapy.Keywords
All Related Versions
Funding Information
- Swiss National Fund (31003A_159590)
- National Institute of Neurological Disorders and Stroke (grant NS089575)
This publication has 58 references indexed in Scilit:
- Endoglin Haplo-Insufficiency Modifies the Inflammatory Response in Irradiated Mouse Hearts without Affecting Structural and Mircovascular ChangesPLOS ONE, 2013
- Enhanced Sensitivity to Low Dose Irradiation of ApoE−/− Mice Mediated by Early Pro-Inflammatory Profile and Delayed Activation of the TGFβ1 Cascade Involved in FibrogenesisPLOS ONE, 2013
- RhoB modifies estrogen responses in breast cancer cells by influencing expression of the estrogen receptorBreast Cancer Research, 2013
- The proliferation rate paradox in antimitotic chemotherapyMolecular Biology of the Cell, 2012
- Gender Differences in Treatment Outcomes among Patients with Non-Small Cell Lung Cancer Given a Combination of Carboplatin and PaclitaxelOncology, 2008
- Anti-cancer drug induced neurotoxicity and identification of Rho pathway signaling modulators as potential neuroprotectantsNeuroToxicology, 2008
- Quantitative Effect of Gender, Age, Liver Function, and Body Size on the Population Pharmacokinetics of Paclitaxel in Patients with Solid TumorsClinical Cancer Research, 2006
- Does neoadjuvant hormone therapy for early prostate cancer affect cognition? Results from a pilot studyBJU International, 2005
- Gender-related differences in myocardial inflammatory and contractile responses to major burn traumaAmerican Journal of Physiology-Heart and Circulatory Physiology, 2004
- Cognitive Function and Reproductive Hormones in Adjuvant Therapy for Breast CancerJournal of Pain and Symptom Management, 2001